Please type a plus sign (+) inside this box →

12-26-07

PTO/SB/21 (06-d)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid MB control number. **Application Number** 10/568,301 **Filing Date** January 26, 2007 RANSMITTAL First Named Inventor Zeng, Fu-Yue **FORM** Group Art Unit 3381 to be used for all correspondence after initial filing) **Examiner Name** Unknown Attorney Docket Number AREN-065 Total Number of Pages in This Submission ENCLOSURES (check all that apply) Fee Transmittal Form Assignment Papers After Allowance Communication (for an Application) to Group Fee Attached Drawing(s) Appeal Communication to Board of Appeals and Interferences Amendment / Reply Licensing-related Papers After Final Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Petition Affidavits/declaration(s) Proprietary Information Petition to Convert to a Extension of Time Request Provisional Application Status Letter **Express Abandonment Request** Power of Attorney, Revocation Change of Correspondence Supplemental Information Other Enclosure(s) (please Address **Disclosure Statement** identify below): Terminal Disclaimer Form PTO/SB/8A (1 pg) Certified Copy of Priority 10 References Return postcard **Documents** Request for Refund Response to Missing Parts/ CD, Number of CD(s Incomplete Application Remarks Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Signing Attorney/Agent **JAMES S. KEDDIE, PH.D., 48,920** (Reg. No.) BOZICEVIC, FIELD & FRANCIS, LLP Signature Date Pebruary 23, 2007

EXPRESS MAIL LABEL NO. EV 577 671 978 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Express Mail No. EV 577 671 978 US

SUPPLEMENTAL					
INFORMATION					
DISCLOSURE STATEMENT					
OFF E					
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \					
FEB 2 3 2007					
Address to:					
Mail Stop Amendment					
Commissioner for Patents					

Attorney Docket	AREN-065	
First Named Inventor	Zeng, Fu-Yue	
Application Number	10/568,301	
Confirmation No.	3381	
Filing Date	January 26, 2007	
Group Art Unit	Unknown	
Examiner Name	Unknown	

Title:

"METHODS AND COMPOSITIONS RELATING TO

MODULATION OF GPCR SIGNALING"

Sir:

P.O. Box 1450

Alexandria, VA 22313-1450

This is a Supplemental Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Supplemental Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. AREN-065 may be charged thereon.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date: February 23, 2007

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303 Telephone: (650) 327-3400

Facsimile: (650) 327-3231

James S. Keddie, Ph.D. Registration No. 48,920

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 1995 (36) control number.

Sheet

FEB 2 3 2007 Substitute for form 1449A/PTO SUPPLEMENTAL INFOR

DISCLOSURE STATEMENT BY APPLY

(use as many sheets as necessary)

Complete if Known				
Application Number	10/568,301			
Filing Date	January 26, 2007			
First Named Inventor	Fu-Yue Zeng			
Group Art Unit	3381			
Examiner Name	unknown			

U.S. PATENT DOCUMENTS						
Date of Publication of Where Relevant or Applicant Cited Document MM-DD-YYYY Figures Appear	Name of Patentee or Applicant of Cited Document	Kind Code ² (if known)	U.S. Pate Number	Cite No.1	Examiner Initials*	
				A1		
				A2		
				A2		

Attorney Docket Number | AREN-0065

						FOREIGN PATENT DOCUMEN	TS			
Examiner Initials*	Cite No.1	Fo Office	oreign Patent [Number4	Document Kind Code (<i>if known</i>)	e ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т	
	B1									
						RT - NON PATENT LITERAT				
Examiner Initials*	Cite No.1					or (in CAPITAL LETTERS), title o nal, serial, symposium, catalog, e publisher, city and/or country wi	tc.), date, page(s), volu		Т	
	C1	SEXTON et al., "Receptor activity modifying proteins," Cellular Signalling (2001) 13:73-83								
·	C2 RIOS et al., "G-protein-coupled receptor dimerization: modulation of receptor function," Pharmacology & Therapeutics (2001) 92:71-87									
	C3 ANGERS et al., "DIMERIZATION: An Emerging Concept for G Protein-Coupled Receptor Ontogeny and Function," Annual Review of Pharmacology and Toxicology (2002) 42:409-435									
	C4	ANGNATI et al., "Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons," Pharmacological Reviews 92003) 55:509-550								
	C5	JOOST et al., "Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands," Genome Biology (2002) 3(11)research0063.1-0063.16:1-16								
	C6 MCVEY et al., "Monitoring Receptor Oligomerization Using Time-resolved Fluorescence Resonance Energy Transfer and B Bioluminescence Resonance Energy Transfer," The Journal of Biological Chemistry (2001) 276-14092-14099									
	C7	HILAIRET et al., "Hypersensitization of the Orexin 1 Receptor by the CB1 Receptor," The Journal of Biological Chemistry (2003) 278-23731-23737								
	С8	XU et al., "Heterodimerization of α _{2A} – and β ₁ – Adrenergic Receptors," The Journal of Biological Chemistry (2003) 278:10770-10777								
	C9	FLOYD et al., "C5a Receptor Oligomerization," The Journal of Biological Chemistry (2003) 278-35354-35361								
	C10	KLCO et al., "C5a Receptor Oligomerization," The Journal of Biological Chemistry (2003) 278:35345-35353								
	C11									

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 3 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 4 Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.